Pluri Inc (PLUR) Stock Price, Quote & News

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 74 710 8600

Website: www.pluri-biotech.com

Address:

Building No. 5, MATAM Advanced Technology Park, Haifa, Israel

Slitherin Aug. 20 at 7:55 PM

Ticker APUS could make people filthy rich. This is a chance to get in a biotech at the ground floor. Their leaders have ties to Novartis which is a $240B corporation They have created a breakthrough pain treatment method using honey bee venom which will disrupt the opioid market . This is a golden opportunity for a 5-10X long term. $PLUR $YMAT $DFDV $HCHL $ASG ON WATCH 🚨

0 · Reply

PLURI_JUGGERNAUT_ Aug. 10 at 11:37 AM

$PLUR August 10th Company Presentation Out !!! https://pluri-biotech.com/presentation/

0 · Reply

PLURI_JUGGERNAUT_ Aug. 4 at 3:06 PM

$PLUR To illustrate the potential, Yanai explains that one large-scale PluriMatrix Cell Expansion System would be equivalent to growing and processing about 500,000 coffee bushes in traditional agriculture. According to him, the Israeli Ministry of Health has already expressed its willingness to be among the world's leading regulators for the approval of cultured products, which can give Israel an advantage in the field of nutritional innovation. "Our goal is not to replace traditional agriculture, but to complement it," Yanai emphasizes. "We tell the farmers: grow as much coffee as you can on the ground, and we will help you supplement the yield with our product." https://www.israelhayom.co.il/tech/tech-news/article/18534641

0 · Reply

Jaimedav Jul. 31 at 12:38 AM

$PLUR … Fraud Alert!!! Another Patent that will never materialize to any revenue. When will this co stop with these BS headlines. Check every company announcement the last 3+ years, all BS.

1 · Reply

PLURI_JUGGERNAUT_ Jul. 28 at 1:50 AM

$PLUR MAIT CELL PATENT !!! 38. The cell composition for use of claim 37, wherein the subject is afflicted with a tumor selected from the group consisting of: blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma. https://worldwide.espacenet.com/patent/search/family/094214915/publication/EP4572789A1?q=pn%3DEP4572789

0 · Reply

PLURI_JUGGERNAUT_ Jul. 24 at 11:25 AM

$PLUR Most Are Going To Raise Prices, Demand Is Strong Supplies Are Limited. Several chocolate companies, including Hershey, Lindt, and Cloetta, are raising prices due to rising cocoa costs. Hershey is implementing a "lower double-digit" percentage increase, while Lindt reported a 15.8% increase in the first half of the year. These price hikes are a direct response to the increasing cost of cocoa beans, a key ingredient in chocolate production

0 · Reply

Jac1962 Jul. 23 at 1:16 PM

$PLUR Hershey Chocolate Raising There Prices.....

0 · Reply

ChelseaFC1 Jul. 22 at 1:23 PM

$PLUR

0 · Reply

RoniToni Jul. 11 at 1:59 PM

$PLUR $PLTR when a liar spreads his words. You can check my charts, and proof me wrong.

0 · Reply

PLURI_JUGGERNAUT_ Jul. 7 at 2:01 PM

$PLUR https://www.gcrmag.com/is-lab-grown-coffee-the-future-of-the-industry/

0 · Reply

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Mar 5, 2025, 7:00 AM EST - 6 months ago

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Feb 19, 2025, 9:01 AM EST - 6 months ago

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Jan 23, 2025, 7:15 AM EST - 7 months ago

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

$Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Dec 19, 2024, 8:00 AM EST - 8 months ago

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Nov 12, 2024, 1:00 PM EST - 10 months ago

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Nov 11, 2024, 6:00 AM EST - 10 months ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Jul 18, 2024, 2:30 AM EDT - 1 year ago

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Jun 18, 2024, 12:45 PM EDT - 1 year ago

Pluri: Biotech Play With Several Opportunities Across Different Sectors

Jun 18, 2024, 6:30 AM EDT - 1 year ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

Jun 6, 2024, 6:45 AM EDT - 1 year ago

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

May 20, 2024, 7:00 AM EDT - 1 year ago

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

May 2, 2024, 7:00 AM EDT - 1 year ago

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Mar 28, 2024, 7:15 AM EDT - 1 year ago

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Pluri Inc. Announces 1-for-8 Reverse Share Split

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Mar 19, 2024, 4:00 AM EDT - 1 year ago

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Mar 6, 2024, 7:00 AM EST - 1 year ago

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Feb 28, 2024, 7:00 AM EST - 1 year ago

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Jan 23, 2024, 2:00 AM EST - 1 year ago

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Jan 8, 2024, 7:00 AM EST - 1 year ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Jul 13, 2023, 2:00 AM EDT - 2 years ago

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Jul 11, 2023, 2:00 AM EDT - 2 years ago

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Apr 27, 2023, 7:00 AM EDT - 2 years ago

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Dec 22, 2022, 7:00 AM EST - 2 years ago

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Dec 15, 2022, 4:05 PM EST - 2 years ago

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Nov 10, 2022, 7:00 AM EST - 3 years ago

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Pluri to Present and Participate in Upcoming Conferences

Sep 29, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Sep 6, 2022, 7:00 AM EDT - 3 years ago

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Jul 25, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Shareholder Update

Jul 25, 2022, 1:00 AM EDT - 3 years ago

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Jul 13, 2022, 9:59 AM EDT - 3 years ago

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

Jul 13, 2022, 6:00 AM EDT - 3 years ago

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Mar 28, 2022, 3:00 AM EDT - 3 years ago

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Mar 23, 2022, 7:30 AM EDT - 3 years ago

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Mar 8, 2022, 7:12 AM EST - 3 years ago

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Mar 2, 2022, 7:00 AM EST - 3 years ago

Pluristem CEO Issues Shareholder Update

Feb 24, 2022, 7:00 AM EST - 3 years ago

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Jan 10, 2022, 6:26 AM EST - 3 years ago

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

Jan 10, 2022, 3:00 AM EST - 3 years ago

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Dec 27, 2021, 7:00 AM EST - 3 years ago

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Nov 15, 2021, 7:10 AM EST - 4 years ago

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Nov 10, 2021, 7:00 AM EST - 4 years ago

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

Slitherin Aug. 20 at 7:55 PM

0 · Reply

PLURI_JUGGERNAUT_ Aug. 10 at 11:37 AM

$PLUR August 10th Company Presentation Out !!! https://pluri-biotech.com/presentation/

0 · Reply

PLURI_JUGGERNAUT_ Aug. 4 at 3:06 PM

0 · Reply

Jaimedav Jul. 31 at 12:38 AM

$PLUR … Fraud Alert!!! Another Patent that will never materialize to any revenue. When will this co stop with these BS headlines. Check every company announcement the last 3+ years, all BS.

1 · Reply

PLURI_JUGGERNAUT_ Jul. 28 at 1:50 AM

0 · Reply

PLURI_JUGGERNAUT_ Jul. 24 at 11:25 AM

0 · Reply

Jac1962 Jul. 23 at 1:16 PM

$PLUR Hershey Chocolate Raising There Prices.....

0 · Reply

ChelseaFC1 Jul. 22 at 1:23 PM

$PLUR

0 · Reply

RoniToni Jul. 11 at 1:59 PM

$PLUR $PLTR when a liar spreads his words. You can check my charts, and proof me wrong.

0 · Reply

PLURI_JUGGERNAUT_ Jul. 7 at 2:01 PM

$PLUR https://www.gcrmag.com/is-lab-grown-coffee-the-future-of-the-industry/

0 · Reply

topstockalerts Jul. 4 at 5:45 PM

$PLUR keep it on your radar for next week.. 👀🍾🍾👀...

0 · Reply

PLURI_JUGGERNAUT_ Jul. 4 at 5:25 PM

$PLUR Pluri Director Voted Out! SEC Gives Pluri 1 Year To Find Another! No Big Deal !!!

0 · Reply

Rage_Against_The_Machine Jul. 3 at 5:32 PM

$PLUR shareholders just voted out a key director, triggering Nasdaq compliance issues. Now facing an audit committee crisis while burning $4M+/quarter with negative equity. This biotech's high-wire act just got wobblier. Next move: find another independent director before regulators lose patience. https://www.sec.gov/Archives/edgar/data/1158780/000121390025061364/ea0248143-8k_pluri.htm

0 · Reply

cyberne Jul. 2 at 6:55 PM

$PLUR are there any recorded conference calls for this company? I'm starting my DD on this stock. Any help is much appreciated.

3 · Reply

MGeronimo Jul. 2 at 2:11 AM

$PLUR in at 4.83 on positive pipeline news

2 · Reply

PLURI_JUGGERNAUT_ Jul. 1 at 12:26 PM

$PLUR July Company Presentation Out !!! https://pluri-biotech.com/presentation/

0 · Reply

PLURI_JUGGERNAUT_ Jun. 30 at 1:23 AM

$PLUR WOW !!! https://worldwide.espacenet.com/patent/search/family/094214915/publication/EP4572789A1?q=pn%3DEP4572789

1 · Reply

Jess_Sherk Jun. 28 at 3:26 PM

$PLUR ya it’s just the cure for Cancer. And Pluri owns all the patents . Potential 1000 dollar stock . Not a joke

0 · Reply

PLURI_JUGGERNAUT_ Jun. 26 at 8:19 PM

$PLUR Are MAIT Cells The Future of CAR-T Immunotherapy? Pluri Mentioned In The Last Paragraph !!! https://www.cas.org/resources/cas-insights/mait-cells

1 · Reply

ExecutiveEdge Jun. 25 at 8:40 PM

ATER ready to explode! check the two recent PRs, and zero borrow+ 1hr and daily up trend! $NCPL $AVAV $TIGR $PLUR

0 · Reply

_www_larval_com_ Jun. 25 at 7:57 PM

$YAAS -8%[-18%] $PLUR 5%[18%] $LIMN -4%[-9%] $NCPL 3%[21%] $XBIO 3%[18%] most notable movement into the final minutes of trading.

0 · Reply

_www_larval_com_ Jun. 25 at 5:42 PM

$PLUR just reverted -9% lower to 3% (~391Kv) a few minutes ago, follow for more volatility.

0 · Reply

Market Cap	35.50M
Revenue (ttm)	330,000.00
Net Income (ttm)	-20.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,330.30%
Debt to Equity Ratio	51.98

Volume	8,300
Avg Vol	31,206
Day's Range	N/A - N/A
Shares Out	7.87M
Stochastic %K	67%
Beta	0.76
Analysts	Strong Buy
Price Target	$12.00